Portola Pharmaceuticals (PTLA) 10-K2019 FY Annual report

Filed: 28 Feb 20, 4:09pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: al, alter, antifraud, ASH, Athyrium, attenuate, Attorney, Austria, avoid, avoiding, biosimilar, Blueprint, Cal, captioned, CCPA, ceiling, charitable, Circuit, Cloud, Coast, commerce, concealing, conserve, constantly, contend, Cosmetic, cutoff, cycle, Delinquent, Denmark, derecognized, dismissal, dispensed, disproportionate, DOD, domestic, expiry, falsifying, FCP, feedback, Finland, fit, flat, formula, FSS, FTC, fuller, GILTI, Guard, harbor, Hayden, head, hindsight, HIPAA, host, hosting, HRSA, illegal, imprisonment, improperly, incentivize, incorrect, Inspector, intentionally, intraoperative, Ireland, JCAHO, lenalidomide, LP, McCutcheon, misleading, misrepresentation, mutual, NaN, noncurrent, Northern, nurse, OIG, organizational, overcharge, overhaul, plaintiff, postmarketing, prevailing, procure, procured, procurement, prompt, punishable, rationalizing, realignment, remanded, reorder, representation, residual, resistance, Retail, retroactive, revealed, Roivant, rural, safeguarding, scrutinize, se, shift, shifting, shipment, software, statutorily, strict, subpart, Subtopic, Sweden, tangible, territorial, transmission, Tricare, turnover, unapproved, uncollectible, undertook, undistributed, unfair, unspecified, untitled, unusual, VA, version, vitiligo, WAC, Wave, wind

Removed: abandoned, absorb, accretion, aCSA, adjudication, advancing, allocating, API, appeal, applying, attainment, batch, bill, branded, calculating, calling, center, chemical, CMC, compensate, concurrent, confirming, copy, CSA, database, de, deep, demonstration, deterioration, disorder, driven, DVT, earlier, economically, eliminating, engineering, ethnic, Euro, eventually, expended, frame, frequently, greatly, guaranteed, Hovione, IDMC, informed, ingredient, inhibit, investigative, invoice, invoiced, JCC, length, linked, Lis, MAA, match, medicine, molecular, noncancelable, notified, paper, partnered, path, pertaining, pipeline, post, pound, prohibit, proposing, proposition, quantified, relied, remained, retrospectively, reviewed, Room, shortened, significance, simultaneously, solid, specialist, split, standalone, strategically, sublicense, supplement, surveillance, symptomatic, synthetic, tenant, toxicology, trace, tracking, twenty, unblinded, uncured, undergo, undermine, uneven, Union, unique, unpaid, validation, vein, weight, whichever, William, withhold

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

PTLA similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), Scott Garland, Chief Executive Officer of Portola Pharmaceuticals, Inc. (the “Company”), and Mardi C. Dier, Executive Vice President, Chief Financial Officer of the Company, each hereby certifies that, to the best of his or her knowledge:


1.	The Company’s Annual Report on Form 10-K for the period ended December 31, 2019 (the “Annual Report”), to which this Certification is attached as Exhibit 32.1, fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act, and


2.	The information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

In Witness Whereof, the undersigned have set their hands hereto as of the 28th day of February 2020.



/s/ Scott Garland		/s/ Mardi C. Dier
Scott Garland		Mardi C. Dier
President and Chief Executive Officer		Executive Vice President and Chief Financial Officer

“This certification accompanies the Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Portola Pharmaceuticals, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.”